Link to article in @AjHematology, also adding other co-authors including @bhemato@DarrenPanMD and more.
Lots of nuances in text around recommendations above, e.g. post-ASCT maintenance and what we'd actually recommend for our own patients (and why).
https://t.co/0kQYmMWtz3
Short survival with BCMA and GPRC5D dual antigen exposed relapsed myeloma [DEMM] - an international myeloma working group [IMWG] immunotherapy database analysis [Nov 3, 2025] @JanakiramMurali et al. #ASH25 abs25-14454 PID 4598 https://t.co/iLZPqH9mOI #mmsm#ImmunoOnc
How should we choose optimal salvage treatments following BCMA-directed CAR-T therapy in multiple myeloma? Check out our review article out today summarizing recent studies and our approach to therapy sequencing from our team @UCSFCancer 👇 #MMsm#myeloma
https://t.co/ab69zXWzTb
We want to share this important toxicity profile of GPRC5D BisAb- Talquetamab.
GPRC5D Bispecific antibody talquetamab-induced dizziness-ataxia syndrome, clinical presentation and management- a case series
https://t.co/Y4f4krHEJQ
Full link- https://t.co/CDKAxwD5J3
We covered the many exciting GPRC5D-based treatments on the horizon, likely to reshape how we treat myeloma - Emerging GPRC5D-Targeted therapies for multiple myeloma: a comprehensive review
@AjaiChari@UCSFCancer
https://t.co/eAWr8E8RmN
Delayed cart neurotox -likely 4 risk factors demographics, disease burden, high grade crs/icans, peak CAR expansion. However rare so requires continued international collaborations- outstanding work by Dr Kumar and global contributors!
Management strategies for bispecific antibodies in myeloma. Strong work by @DarrenPanMD. Ending the decades old east coast / west coast rivalry. @UCSFCancer @TischCancer #mmsm https://t.co/AmtyHOHoRb
I’m beyond touched to receive this from @DarrenPanMD He says that I always have myeloma on my mind. 😀. Looking forward to years of collaboration between @UCSFCancer and @TischCancer #mmsm
4 years later, after dark nights on the front lines of the Covid alpha wave @DOMSinaiNYC together, we're now fighting cancer in our own way. Thank you patients, donors, @ConquerCancerFd for your support in us. Barbara Murphy this one's for you! #ASCO24
#ASH23 | 🎥 The Multiple Myeloma Hub spoke to @DarrenPanMD, @IcahnMountSinai, US. We asked, Are chimeric antigen receptor T-cell therapies effective in the treatment of extramedullary multiple myeloma?
Watch the video here: https://t.co/CxOPczzQpW
#mmsm#myeloma#MultipleMyeloma
Darren Denjay Pan on Multiple Myeloma Inflammatory Biomarkers and Outcomes After CAR T-Cell Therapy - The ASCO Post. Amazing work @DarrenPanMD #mmsm @TischCancer @MountSinaiNYC https://t.co/KYac8CXwQx